Press release


05/09/2013
Algenex increases production of raw material to supply Boehringer Ingelheim Vetmedica (BIV)
ALGENEX is proud to announce that it is increasing its production in Madrid to support its licensee, Boehringer Ingelheim Vetmedica (BIV), with sufficient virus recombinant antigens, a key raw material for use in SVANOVIR® ASFV-Ab, a kit for the serological diagnosis of African Swine Fever.
 
ALGENEX is proud to announce that it is increasing its production in Madrid to support its licensee, Boehringer Ingelheim Vetmedica (BIV), with sufficient virus recombinant antigens, a key raw material for use in SVANOVIR® ASFV-Ab, a kit for the serological diagnosis of African Swine Fever.
Boehringer Ingelheim Svanova, a fully owned subsidiary of BIV, is a leading diagnostics company for animal health and was successful in winning major tenders for the Russian and the Chinese market. ALGENEX and Boehringer Ingelheim Svanova collaborate since 2009 on the design, development and production of this highly relevant diagnostic kit for the swine industry. SVANOVIR® ASFV-Ab was first launched in November 2011 and sales have been growing steadily.
As all recombinant proteins are made with the proprietary IBES® technology, expanding the supply of these products is also a major commercial validation for the added value ALGENEX is bringing to its customers.

About ALGENEX
Algenex is a Spanish start-up company involved in developing new platforms, more versatile and powerful, to produce high added value molecules to both human and animal health in a cost-effective manner. Algenex has developed two disruptive platforms within baculovirus expression vector system (BEVS) to achieve these goals. Top-Bac® is a proprietary expression cassette that improves the quality of protein produced and in most of the cases quadruplicate the production over conventional BEVS in insect cells. The other platform of Algenex is IBES®, which is based on the use of insect larvae as disposable, living bioreactors. The combination of both platforms leads to unprecedented yields of one of the most powerful BEVS-based technologies.
 
 
Related links:
 
 
Permalink  
 
Developed by Web4Bio